BioTech & Genomics: 2026 Valuation Multiples

Advancement in BioTechnology have been fundamental in key breakthroughs in modern medicine, allowing us to treat and cure conditions that were considered irreversible until just a few years ago. While BioTech and genomics played a key role in the worldwide response to the COVID-19 pandemic, recent industry growth has been overwhelmingly driven by the explosion of glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and diabetes.

In fact, GLP-1 therapies have recently displaced oncology as the largest contributor to late-stage pipeline value, fuelling a massive market opportunity projected to reach well over $100 billion in value. The late 2025 and early 2026 approvals of oral GLP-1 pills from giants like Novo Nordisk and Eli Lilly, alongside expanded Medicare and Medicaid coverage, have pushed these weight-loss therapeutics from niche treatments into mainstream public health interventions.

BioTech companies operate in a highly regulated market with a few huge players and intense M&A activity both in public and private markets. There are a few other characteristics that make this sector unique in terms of risk profile, profitability and valuation:

1. Firstly, BioTech and pharmaceutical companies go through a much longer path to revenue and profitability during which they incur huge costs for R&D throughout the discovery process for new drugs and treatments. It has been estimated that developing a successful drug costs over $2.6bn on average according to recent estimates.
2. While for most industries business success can be measured on a spectrum that resembles a gaussian curve, new medical treatments can either be effective or not. Therefore, the risk profile tends to be binary and its assessment can change radically during the trialling process.
3. Revenue streams for BioTech companies vary based on the type of condition that they aim to treat or cure. Some drugs must be administered regularly throughout the patient’s whole lifetime, while treatments—especially those involving gene therapy—that aim to permanently cure a patient have a different revenue model.
4. Finally, the cost of providing cutting-edge cures and therapy is often extremely high because it requires advanced machinery, materials and chemical compounds that are scarce or hard to manufacture.

For the reasons above, calculating valuations for BioTech and Genomics companies usually relies on slightly different techniques than most sectors. Risk-Adjusted NPV and Comparable Companies Analysis are the prominent techniques as they avoid relying on financial metrics such as revenue and profits, which aren’t always available even for larger companies.

In fact, about 80% of the Nasdaq Biotech Index components are loss-making, which is very atypical for publicly listed companies. BioTech companies are regularly acquired at multi-billion valuations even before they make their first revenues, with aggregate M&A deal value reaching $133 billion in 2025 as large pharmas continue to target early-stage assets to replenish pipelines ahead of looming patent cliffs.

With these caveats in mind, we wanted to provide a statistical analysis of revenue multiples for public BioTech and Genomics companies as a means of comparison, given that multiples alone are not sufficient to substantiate a valuation and the appropriate risk assessment and due diligence of the individual company’s pipeline is still necessary.

The Global X Genomics & Biotechnology ETF (GNOM), managed by Mirae Asset Financial Group, “in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.”

The 41 companies in the fund are all listed on public stock exchanges, and so their financial metrics may differ from younger start-ups introducing innovative technologies, typically considered a high-risk-high-reward investment. Around 80% of these companies recorded revenue throughout the past 2 years, and less than 25% made a profit.

Genomics & BioTech Valuation Multiples

Revenue multiples for BioTech & Genomics companies grew throughout all of 2020, peaking at a median of 15.19x in Q4 2020. After a continued fall throughout all of 2021 and 2022, revenue multiples stabilised between the 4.5x and 6.5x mark throughout 2023 and 2024. Over the course of 2025, multiples compressed further, dropping to a low of 3.8x in Q2 before recovering slightly. In Q1 2026, the median EV/Revenue Multiple for BioTech & Genomics companies sat at 4.4x.

Source: YCharts

The distribution of revenue multiples is heavily skewed to the right, with the vast majority of companies staying below the 10x mark for the past three years. A far cry from the peak at the end of 2020, when the sector rose to prominence likely thanks to COVID-19 vaccine breakthroughs.

The top 25% of companies by revenue multiples, which constitutes the ‘long tail’ of the sample, still managed to reach significant peaks in recent quarters, with maximum outlier valuations passing the 32x mark at the end of 2025 (32.53x in Q4 2025), and hitting a peak of 18.58x in Q1 2026. In the analysis, the Interquartile Range (IQR) has remained relatively tight in 2025 and 2026, highlighting where the median 50% of the cohort consistently ranks based on their valuation multiple.

Source: YCharts In the chart above, the lines indicate the range of EV/Revenue multiples in our cohorts, while the boxes highlight the Interquartile Range (IQR), which is where the median 50% of the cohort ranks based on their valuation multiple.